Olaparib is an oral poly (adenosine diphosphate–ribose) polymerase inhibitor that has been compared with single-agent chemotherapy in an RCT involving 302 women with advanced HER2-negative BC with a germline BRCA mutation [98]. This evidence concerns the gene ERBB2 and breast cancer.